Kidney Cancer | Tumor

CURE’s kidney cancer page is an extensive resource of cancer information featuring the latest kidney cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on kidney cancer.

Immunotherapy for Frontline Treatment of Kidney Cancer Has ‘Curative Potential’

November 3rd 2021

An expert discusses how the kidney cancer treatment landscape has changed over the last few years, although the number of options available for patients may make it somewhat confusing to navigate.

Available Treatment Options for von Hippel-Lindau Disease

November 3rd 2021

CURE spoke with Stacy Lloyd, board member of the VHL Alliance, about the treatment options for patients with VHL.

The Basics of von Hippel-Lindau Disease

November 3rd 2021

CURE spoke with Stacy Lloyd, board member of the VHL Alliance, to better understand VHL and its impact on cancer.

Discussing Hereditary Cancer, VHL Disease With One’s Family

November 2nd 2021

As a part of its “Speaking Out” video series, CURE spoke with Stacy Lloyd on behalf of the VHL Alliance, about discussing hereditary cancer with family members and how a diagnosis can lead to earlier surveillance for the disease.

Disparities in von Hippel-Lindau Disease

November 2nd 2021

CURE spoke with Stacy Lloyd, board member of the VHL Alliance, about disparities seen in VHL and its patient population.

Patient Resources and Support for von Hippel-Lindau Disease

November 2nd 2021

CURE spoke with Stacy Lloyd, board member of the VHL Alliance, about VHL as a rare disease and resources available for patients to learn more.

Weighing the Risks and Benefits of Adjuvant Therapy for Kidney Cancer

November 2nd 2021

Some patients with kidney cancer who are at a high risk of disease recurrence may benefit from adjuvant therapy; however, it is important recognize the potential side effects.

Know Your Treatment Options for Kidney Cancer: ‘Every Patient Is Different’

November 1st 2021

An expert explains the various treatment options available for a patient who is diagnosed with a small renal mass.

Surveillance Is a ‘Balance of Risk’ and Should Be Considered for Kidney Tumors

October 28th 2021

Some patients with small kidney tumors may be able to forego treatment and have regular medical checkups instead.

Educated Patient® Kidney Cancer Summit: October 24, 2021

October 24th 2021

View the full CURE Educated Patient Kidney Cancer Summit on demand.

Here's Why Collaboration Is Important for Progress in Genitourinary Cancers

September 26th 2021

It is important that the whole community understand that basic research and clinical trials can continue to improve outcomes for patients with genitourinary cancer.

Inside the Shifting Treatment Landscape for Advanced Genitourinary Cancers

September 25th 2021

In this special issue of CURE®, we spoke with patients and health care providers about fertility issues, treatment advancements and other topics related to kidney, prostate, testicular and bladder cancers.

In Understanding Kidney Cancer Treatments, ‘Knowledge Is Power’

September 21st 2021

Patients and caregivers of those with kidney cancer can become active members in their care by staying up to date on the latest treatments and medical advances.

Lack of Smoking Data in Bladder, Kidney and Prostate Cancer Clinical Trials May Affect Patient Outcomes

September 17th 2021

Clinical trials that are designed to ask patients with bladder, kidney and prostate cancer about their smoking status may help patients better understand what to expect from their treatment based on their smoking habits.

Novel Combinations Offer New Hope in Kidney Cancer

September 13th 2021

Immunotherapy and tyrosine kinase inhibitors may potentially change the treatment paradigm for patients with renal cell carcinoma, the most common type of kidney cancer in adults.

Cholesterol-Blocking/Hepatitis C Antiviral Drugs May Work on Kidney Cancer

August 26th 2021

Inhibiting a cholesterol receptor could prevent a certain type of kidney cancer from growing, according to recent research.

FDA’s Welireg Approval A ‘Complete Game Changer’ for Certain Cancers Associated With VHL Disease

August 24th 2021

The approval of Welireg, according to an expert at Massachusetts General Hospital, is “extremely important” and will “dramatically” change how certain von Hippel-Lindau-associated cancers are treated.

Keytruda-Lenvima Combo for Advanced Renal Cell Carcinoma Signifies ‘a Great Time for the Field’

August 20th 2021

Frontline Keytruda plus Lenvima for advanced renal cell carcinoma is an effective treatment with life-prolonging benefits, although patients should be monitored for side effects that can be easily managed.

FDA Approves Welireg for Several Cancers Associated With VHL Disease

August 13th 2021

The FDA granted approval to Welireg for the treatment of patients with von Hippel-Lindau-associated kidney cancer, CNS hemangioblastomas and pancreatic neuroendocrine tumors.

FDA Approves Keytruda Plus Lenvima for Frontline RCC Treatment

August 12th 2021

Patients on Keytruda/Lenvima lived for an average of 23.9 months without their disease progressing, compared to those on a different treatment, with an average of 9.3 months.

FDA Grants Keytruda Priority Review for Kidney Cancer Treatment

August 10th 2021

The FDA will speed up the review of Keytruda to treat patients with kidney cancer after they’ve undergone surgery.

Women With Diabetes May Face Increased Kidney Cancer Risk

July 26th 2021

Post-menopausal women may be at an increased risk for kidney cancer if they are diagnosed with type 2 diabetes.

Inequality in Kidney Cancer Treatment Affects Decision-Making

July 19th 2021

The risk for under- or over-treatment for kidney cancer may be higher in women, in addition to Black and Hispanic patients.

Minnesota Congressman Jim Hagedorn’s Cancer Returned, A Three-time Survivor Plans to Bike 100 Miles and More

July 9th 2021

From the recurrence of congressman Jim Hagedorn’s kidney cancer to a 100-mile bike race for charity, here’s what’s happening in the cancer landscape this week.

Lenvima-Keytruda Combo Shows Superior Benefit Over Sutent Across Several Subgroups of Patients with Kidney Cancer

June 28th 2021

The combination of Lenvima and Keytruda was associated with improvements in survival and response rates over Sutent alone in various subgroups of patients with advanced renal cell carcinoma.

Novel Drug Induces Robust Responses in von-Hippel Lindau Disease-Associated Kidney Cancer

June 24th 2021

At a median follow-up of almost two years, 88.5% of patients remained on study treatment.

Man With Late-Stage Cancer Gets Matching Tattoos with Strangers, Elderly Cancer Survivor Earns Black Belt in Taekwondo

June 18th 2021

From a man with late-stage cancer who has matching tattoos with over 400 strangers to a 78-year-old cancer survivor getting his black belt in Taekwondo, here’s what’s happening in the cancer landscape this week.

Keytruda-Inlyta Combo Continues to Improve Survival in Kidney Cancer

June 10th 2021

Use of the combination of Keytruda and Inlyta is associated with long-term survival benefits in patients with kidney cancer.

Fotivda Nearly Doubles Duration of Response Compared With Nexavar in Metastatic Kidney Cancer

June 6th 2021

In patients with metastatic renal cell carcinoma whose disease failed to respond to two prior therapies, Fotivda, compared with Nexavar, contributed to a duration of response of 20.3 months versus 9 months.

Keytruda After Surgery Significantly Improves Survival in Patients with Kidney Cancer

June 4th 2021

Treatment with Keytruda following surgery was associated with a significant reduction in the risk of disease recurrence or death compared with placebo in patients with clear cell renal cell carcinoma.